Comparison · NCT03409107-sae
Daprodustat vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Daprodustat vs Placebo: serious adverse events. Trial comparisons, record NCT03409107-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03409107-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.201 | 0.16 | 0.25 | wilson | |
| Risk in group 2 | 0.222 | 0.179 | 0.272 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0209 | -0.0855 | 0.0438 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.906 | 0.667 | 1.23 | log | |
| Odds ratio, group 1 over group 2 | 0.882 | 0.599 | 1.3 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Daprodustat than on Placebo | 47.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Daprodustat | Participants received daprodustat tablets with titrated dose levels ranging from 1, 2, 4, 6, 8, 10, 12, 16 milligrams (mg) once daily orally for up to 28 weeks, followed by 4 weeks of follow-up. Study treatment was dose-titrated to achieve and maintain hemoglobin in the target range (11 to 12 grams per deciliter \[g/dL\]) | 62 | 308 | EG001 |
| Group 2 | Placebo | Participants received matching placebo once daily orally for up to 28 weeks followed by 4 weeks of follow-up. | 68 | 306 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All cause mortality, serious adverse events (SAEs) and non-serious AEs were collected up to follow-up (Week 32).
Source ClinicalTrials.gov
Trial
- Title
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
- NCT number
- NCT03409107
- Phases
- PHASE3
- Conditions
- Anaemia
- Interventions
- Daprodustat (GSK1278863), Placebo, Iron therapy
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2021-11-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03409107?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03409107-sae